# Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

> **NCT00115349** · PHASE2 · TERMINATED · sponsor: **Carelon Research** · enrollment: 20 (actual)

## Conditions studied

- Cardiovascular Diseases
- Heart Diseases
- Beta-Thalassemia

## Interventions

- **DRUG:** Deferoxamine
- **DRUG:** Deferiprone (L1)

## Key facts

- **NCT ID:** NCT00115349
- **Lead sponsor:** Carelon Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06
- **Primary completion:** 2008-07
- **Final completion:** 2009-04
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** due to low enrollment
- **Last updated:** 2018-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115349, "Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00115349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*